Panel Discussion: Neuropsychiatry at a Crossroads: Where Science, Strategy & Deal Making Converge
9:00 am - Wednesday 16th September 2026
- What are the key neuropsychiatry priorities currently shaping strategy at Lilly, AbbVie and Lundbeck?
- To what extent is business development becoming a critical lever for growth and portfolio expansion?
- Which mechanisms, symptoms and indications are generating the greatest excitement and investment across the field?
- What does the future of psychiatry look like, and where will the next wave of innovation come from?
